Extracorporeal Membrane Oxygenation Can Affect Posaconazole Exposure in Critically Ill Patients
ECMO patients may be at an increased risk of subtherapeutic posaconazole concentrations for treating IFI, and ECMO decannulation may increase concentrations. Close therapeutic drug monitoring is recommended, especially during ECMO initiation and decannulation, to ensure posaconazole concentrations are appropriate for treating or preventing IFI.
Authors
- Bradley J. Gardiner (ORCID: https://orcid.org/0000-0001-5609-3937)
- Rekha Pai Mangalore (ORCID: https://orcid.org/0000-0002-8447-6836)
- Miranda Paraskeva (ORCID: https://orcid.org/0000-0002-8223-7305)
- Joshua Ihle (ORCID: https://orcid.org/0000-0001-7867-3713)
- Steven McGloughlin
- Ming G. Chai
Institutions
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1097/ftd.0000000000001437
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00